CAFTA Raises Industry Concerns

Published Online: Saturday, October 1, 2005

Key provisions of the proposed new Central American Free Trade Agreement (CAFTA) could create roadblocks to the introduction of lower-priced generic medicines in the United States, officials at the Generic Pharmaceutical Association (GPhA) warned. Their concerns are focused on CAFTA's intellectual property provisions, which industry leaders describe as in conflict with both US law and commitments made by the World Trade Organization.

Among the chief worries cited by the association are provisions relating to patent extensions for certain drugs; a 5- year minimum period of market exclusivity; omission of the mandatory Bolar provision allowing generic manufacturers to conduct research prior to the expiration of a patent; and failure to require timely resolution of patent disputes.

According to a spokesman for the association, "GPhA is concerned that such measures could block generic drug exports abroad, substantially delay the timely access to affordable pharmaceuticals in those territories, and create the means to delay generic competition here at home, such as through international harmonization measures."

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues